yes but, if in a trial, if one arm performs substantially different than the control arm (e.g. 50% or even 100% lower death rate), the large difference between arms can lead to investigators ending the trial early

ironically, this happened in a previous 2019 trial of Remdemsivir, for a different virus, Ebola

in that trial, 4 drugs for Ebola were tested, including Remdemsivir. 2 non-Remdemsivir drugs succeeded substantially--the large difference between those drugs and Remdemsivir, was enough to cause the investigator to end the trial early and drop Remdemsivir

ironically, the investigator for that trial was none-other-than Dr. Fauci. Maybe that's why he hasn't mentioned Remdemsivir much on TV these days, based on his past professional disappointing experience with Remdemsivir

also, double ironically, Remdemsivir was initially designed to treat Ebola virus, not for flu or coronavirus type viruses. The fact that after the Ebola trial, Remdemsivir was declared not that effective for Ebola (the very virus Remdemsivir was created for), means there is even less of a chance Remdemsivir will prove to be effective for Covid-19 in the current trials

https://www.sciencemag.org/news/2019/08/finally-some-good-ne...